Latest Breaking News On - Head of regulatory affairs at codiak biosciences - Page 1 : comparemela.com

WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,

Praveen tipirneniJoanne gibbonsChris erdmanRegulatory affairs at biogenRegulatory affairsTufts universityRegulatory affairs at morphic therapeuticExchange commissionSecurities exchangeHead of regulatory affairs at codiak biosciencesClinical developmentRegulatory affairs at wave life sciencesSenior vice presidentVice presidentChief executive officerCodiak biosciences